Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
First Claim
Patent Images
1. A method of improving the therapeutic index of a BRM, the method comprising the step of:
- administering a BRM to a secondary lymphoid organ of a subject in a lymphatically effective dose wherein the lymphatically effective dose avoids or reduces a BRM-related adverse clinical event as compared to use of a non-lymphatically effective dose of the BRM.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention includes use of a biological response modifier (BRM) to modulate an immune response in a subject while avoiding or limiting common side-effects associate with BRM use. The BRMs of the present invention can be injected into a secondary lymphatic organ of the subject or into an area of relatively high drainage into a secondary lymphatic organ of the subject. The modulated immune response can be general or antigen-specific.
-
Citations
39 Claims
-
1. A method of improving the therapeutic index of a BRM, the method comprising the step of:
administering a BRM to a secondary lymphoid organ of a subject in a lymphatically effective dose wherein the lymphatically effective dose avoids or reduces a BRM-related adverse clinical event as compared to use of a non-lymphatically effective dose of the BRM. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)
-
34. A method of modulating an antigen-specific immune response, the method comprising the step of:
administering a BRM to a secondary lymphoid organ of a subject in a dose sufficient to obtain a modulated immune response.
-
35. A method of modulating an immune response to an antigen comprising the step of:
co-administering a BRM and said antigen to a secondary lymphatic organ whereby the antigen-specific immune response is modulated, wherein the modulation does not consist essentially of an augmented CTL response.
-
36. A composition comprising a lymphatically effective dose of a BRM, wherein said lymphatically effective dose comprises an amount of a BRM that is relatively nontoxic and wherein said lymphatically effective dose is less than a non-lyphatically effective dose.
-
37. A composition comprising a lymphatically effective dose of a BRM, wherein said lymphatically effective dose comprises an amount of a BRM that is relatively non-toxic and wherein the amount of the BRM is insufficient to be a non-lyphatically effective dose.
-
38. A composition comprising a lymphatically effective dose of a BRM and an antigen, wherein said lymphatically effective dose comprises an amount of a said lymphatically effective dose comprises an amount of a BRM that is relatively non-toxic and wherein the amount of the BRM is insufficient to be a non-lyphatically effective dose.
-
39. A composition comprising a lymphatically effective dose of a BRM wherein said lymphatically effective dose of a BRM is at least ten-fold less than the corresponding non-lyphatically effective dose.
Specification